Form 4: Puma Biotechnology CEO Alan Auerbach Sells Shares Under 10b5-1 Plan

Alan Auerbach, CEO of Puma Biotechnology, sold 21,920 shares of common stock at an average price of $3.7011 on July 17, 2024, under a pre-existing 10b5-1 trading plan.

Summary

• Alan H. Auerbach, the President and CEO of Puma Biotechnology, sold 21,920 shares of the company's common stock on July 17, 2024.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on December 17, 2020.
• The shares were sold at a weighted average price of $3.7011, with individual transaction prices ranging from $3.6001 to $3.8901.
• Following the transaction, Auerbach directly owns 7,063,515 shares of Puma Biotechnology.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the specified range upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like CEOs and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any recent non-public information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
• The sale does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates